Johnson & Johnson (NYSE:JNJ) Shares Bought by Lifestyle Asset Management Inc.

Lifestyle Asset Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 7.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,671 shares of the company’s stock after buying an additional 111 shares during the quarter. Lifestyle Asset Management Inc.’s holdings in Johnson & Johnson were worth $277,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth about $32,000. Conquis Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $36,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays cut their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Finally, Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $153.39 on Thursday. The business has a fifty day simple moving average of $153.81 and a 200-day simple moving average of $153.67. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market cap of $369.07 billion, a P/E ratio of 23.07, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.